^ 7 E‘ ^EJ‘^T S -...
24
Transcript of ^ 7 E‘ ^EJ‘^T S -...
^ 7 ‘E ^ E ‘J ^ T S
1. Abeloff, Martin et al. Clinical Oncology (3"' edn), St. Louis, Mo.: Elsevier Churchill Livingstone. 2004: 2834-39.
2. Advani S, Pai S, Venzon D, et al. Acute lymphoblastic leukemia in India; an analysis of prognostic factors using a single treatment regimen. Ann Oncol. 1999 Feb; 10(2): 167-76.
3. Advani SH, Charak BS, Banavali SD, et al. Acute non-lymphoblastic leukemia in children: prognostic factors and results of chemotherapy. Indian Pediatr. 1990 Jan;27(l): 14-20.
4. Advani SH, Jussawalla DJ, Rao DN, et al. A study of 1126 leukaemia cases- epideraiologic and end result analysis. Indian J Cancer. 1979 Jun;16(2):8-17.
5. Advani SH, Rao DN, Kutty PM, et aJ. Acute non-Jymphoblastic leukaemia in Indian population FAB classification and response to therapy. Indian J Cancer. 1983 Jul- Aug;20(3): 131-6.
6. Agarwal V, Dabadghao S, Misra MN, et al. Immunophenotypic subsets in acute lymphoblastic leukemia from a single centre in North India: correlation with outcome to induction chemotherapy. Indian J Cancer. 2001 Jun;38(2-4):85-91.
7. Ahlbom A, Day N, Feychting M, et al. A pooled analysis of magnetic fields and childhood leukaemia. Br J Cancer. 2000 Sep;83(5):692-8.
8 . Alexander FE, Patheal SL, Biondi A, et al. Transplacental chemical exposure and risk of infant leukemia with MLL gene fusion. Cancer Res. 2001 Mar 15;61(6):2542-6.
9. Allen RT, Hunter WJ, 3rd, Agrawal DK. Morphological and biochemical characterization and analysis of apoptosis. J Pharmacol Toxicol Methods. 1997 Jun;37(4):215-28.
10. Amare P, Gladstone B, Varghese C, et al. Clinical significance of cytogenetic findings at diagnosis and in remission in childhood and adult acute lymphoblastic leukemia: experience from India. Cancer Genet Cytogenet. 1999 Apr;l 10(l):44-53.
11. Andreeff M. Cell kinetics of leukemia. Semin Hematol. 1986 0ct;23(4):300-14.12. Andreeff M. Flow cytometry of Leukemia. In: Melamed MR, Lindmo T, Mendelsohn
ML, (eds). Flow cytometry and sorting. New York:Wiley-Liss, 1990:697-724.13. Appelbaum FR, Baer MR, Carabasi ME, et al. National Comprehensive Cancer
Network. NCCN Practice Guidelines for Acute Myelogenous Leukemia. Oncology (Williston Park). 2000 Nov; 14(11A):53-61.
14. Arber DA, Snyder DS, Fine M, et al. Myeloperoxidase immunoreactivity in adult acute lymphoblastic leukemia. Am J Clin Pathol. 2001 Jul;116(l):25-33.
15. Aref S, Mabed M, El-Sherbiny M, et al. Cyclin DI expression in acute leukemia. Hematology. 2006 Feb;l l(l):31-4.
16. Arlin ZA, Ahmed T, Mittelman A, et al. Higher cure rates in acute leukemia: now more probable with increasingly effective induction therapy. Int J Clin Lab Res. 1992;21(4>:273-7.
17. Arslan O, Akan H, Beksac M, et al. Lack of prognostic value of CD34 in adult AML. Leuk Lymphoma. 1996 Sep;23( 1-2): 185-6.
18. Ashkenas J, Werb Z. Proteolysis and the biochemistry of life-or-death decisions. J Exp Med. 1996 May 1;183(5):1947-51.
19. Attardi LD, Jacks T. The role of p53 in tumour suppression: lessons from mouse models. Cell Mol Life Sci. 1999 Jan;55(l):48-63.
20. Bahia DM, Yamamoto M, Chauffaille Mde L, et al. Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical significance. Haematologica. 2001 Aug;86(8):801-6.
21. Bajel A, George B, Mathews V, et al. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol. Pediatr Blood Cancer. 2008 Nov;51(5):621-5.
22. Baldin V, Lukas J, Marcote MJ, et al. Cyclin Dl is a nuclear protein required for cell cycle progression in Gl, Genes Dev. 1993 May;7(5):812-21.
170
23. Ball ED, Davis RB, Griffin JD, et ai. Prognostic value of lymphocyte surface markers in acute myeloid leukemia. Blood. 1991 May 15;77(10);2242-50.
24. Basso G, Lanza F, Orfao A, et al. Clinical and biological significance of CD34 expression in acute leukemia. J Biol Regul Homeost Agents. 2001 Jan-Mar;15(l):68-78.
25. Basso G, Rondelli R, Putti MC, et al Incidence and prognostic significance of immunophenotypic subgroups in childhood acute lymphoblastic leukemia: the experience of the AJEOP Cooperative Study. Associazione Italiana Ematologia Oncoiogia Pediatrica. Recent Results Cancer Res. 1993; 131:297-307.
26. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev. 1996 Feb;6(l): 12-8.
27. Belson M, Kingsley B, Holmes A. Risk factors for acute leukemia in children: a review. Environ Health Perspect. 2007 Jan; 115(1): 138-45.
28. Bene MC, Bernier M, Casasnovas RO, et al. Acute myeloid leukaemia MO: haematological, immunophenotypic and cytogenetic characteristics and their prognostic significance: an analysis in 241 patients. Br J Haematol. 2001 Jun;l 13(3):737-45.
29. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995 0ct;9(10): 1783-6.
30. Bennett J et. al. Proposal for the classification of the acute leukemias. Br J Hematol 33, 451,1976.
31. Bennett JH. Case of hypertrophy of the spleen and liver, in which death took place from suppuration of the blood. Edinburgh Medical and Surgical Journal. 1845 (64):413-23.
32. Bennett JM, Catovsky D, Daniel MT et al. Practical value of cytochemical reactions. In Practical Haematology (8* edn). Sir John Dacie and SM Lewis (eds), Churchill Livingstone, Edinburgh, 1994.154-55.
33. Bennett JM, Catovsky D, Daniel MT, et al. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol. 1981 Apr;47(4):553-61.
34. Bernier M, Massy M, Deleeuw N, et al. Immunological definition of acute minimally differentiated myeloid leukemia (MO) and acute undifferentiated leukemia (AUL). Leuk Lymphoma. 1995;18Suppl 1:13-7.
35. Bhargava M, Kumar R, Karak h, et al. Immunological subtypes of acute lymphoblastic leukemia in north India. Leuk Res. 1988;I2(8):673-8.
36. Bincoletto C, Saad ST, da Silva ES, et al. Haematopoietic response and bcl-2 expression in patients with acute myeloid leukaemia. Eur J Haematol. 1999 Jan;62(l):38-42.
37. Bishop JF, Matthews JP, Young GA, et ai. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood. 1996 Mar 1;87(5):1710~7.
38. Bishop JF. The treatment of adult acute myeloid leukemia. Semin Oncol. 1997 Feb;24(l):57-69.
39. Boldt DH, Kopecky KJ, Head D, et al. Expression of myeloid antigens by blast cells in acute lymphoblastic leukemia of adults. The Southwest Oncology Group experience. Leukemia. 1994 Dec;8(12):2118-26.
40. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin. 1993 Jan- Feb;43(l):7-26.
41. Borowitz MJ, Gockerman JP, Moore JO, et al. Clinicopathologic and cytogenic features of CD34 (My 10)-positive acute nonlymphocytic leukemia. Am J Clin Pathol.1989 Mar;91(3):265-70.
42. Borowitz MJ, Shuster JJ, Civin Cl, et al. Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 1990 Aug;8(8): 1389-98.
171
43. Bosanquet AG. Correlations between therapeutic response of leukaemias and in-vitro dnig-sensitivity assay. Lancet. 1991 Mar 23;337(8743):7! i-4.
44. Boucheix C, David B, Sebban C, et a!. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood. 1994 Sep 1;84(5): 1603-12
45. Bradstock K, Matthews J, Benson E, et al. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood. 1994 Aug 15;84(4): 1220-5.
46. Brondum J, Shu XO, Steinbuch M, et al. Parental cigarette smoking and the risk of acute leukemia in children. Cancer. 1999 Mar 15;85(6): 1380-8.
47. Brow man GP, Neame PB, Soamboonsrup P. The contribution of cytochemistry and immunophenotyping to the reproducibility of the FAB classification in acute leukaemia. Blood. 1986 Oct;68(4);900-5.
48. Brown JM, Wouters BG. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res. 1999 Apr l;59(7):1391-9.
49. Buchner T. Treatment of adult acute leukemia. Curr Opin Oncol. 1997 Jan;9(l): 18-25.50. Buckley JD, Robison LL, Swotinsky R, et al. Occupational exposures of parents of
children with acute nonlymphocytic leukemia: a report from the Childrens Cancer Study Group. Cancer Res. 1989 Jul 15;49(14):4030-7.
51. Bueso-Ramos CE, Yang Y, deLeon E, et al. The human MDM-2 oncogene is overexpressed in leukemias. Blood. 1993 Nov 1;82(9);2617-23.
52. Byrd JC, Mrozek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia; results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002 Dec 15;100(13);4325-36.
53. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood. 1992 Jan 15;79(2):473-6.
54. Campos L, Guyotat D, Archimbaud B, et al. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy, BrJ Haematol. 1989 Jun;72(2): 161-6.
55. Campos L, Rouault JP, Sabido 0, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993 Jun I;81(ll);3091-6.
56. Canalle R, Burim RV, Tone LG, et al. Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Environ Mol Mutagen. 2004;43(2); 100-9.
57. Carter BZ, Komblau SM, Tsao T, et al. Caspase-independent cell death in AML; caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis. Blood. 2003 Dec l;102(12);4179-86.
58. Cascavilla N, Miisto P, D’Arena G, et al. Adult and childhood acute lymphoblastic leukemia; clinico-biological differences based on CD34 antigen expression, Haematologica. 1997 Jan-Feb;82(l):31-7.
59. Cassileth PA, Harrington DP, Hines JD, et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol. 1988 Apr;6(4);583-7.
60. Chang H, Salma F, Yi QL, et al. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk Res. 2004 Jan;28(l):43-8.
61. Chatterjea JB, Ghose S, Ray RN. Incidence of leukaemia. (An analysis of 544 cases studied in Calcutta). J Assoc Physicians India. 1962 Dec;10:673-6.
62. Chaudhary K et al. Cancer in India. Report prepared by Division of Non- Communicable Diseases, ICMR, Ansari Nagar, New Delhi-29.1996.
172
63. Chen BG, Zhang L, Li BL, et al. [Sensitivity and specificity analysis of the lineage related antibodies in acute leukemia immunophenotyping by flow cytometry.] Zhongguo Shi Yaa Xue Ye Xue Za Zhi. 2005 Apr;13(2):329-31.
64. Chen YH, Tang YM, Shen HQ, et al. [The expression of CD19 in 210 cases of childhood acute leukemia and its significance] Zhonghua Er Ke Za Zhi. 2004 Mar;42(3); 188-91. Chinese.
65. Chianese R, Brando B, Gratama JW; European Working Group on Clinical Cell Analysis. Diagnostic and prognostic value of flow cytometric immunophenotyping in malignant hematological diseases. J Biol Regul Homeost Agents. 2002 Oct- Dec;16(4):259-69.
66. Chovi' KU, Rummel MJ, Weidmann E, et al. Induction of apoptosis by 2-chloro- 2’deoxyadenosine (2-CdA) alone and in combination with other cytotoxic drugs: synergistic effects on normal and neoplastic lymphocytes by addition of doxorubicin and mitoxantrone. Leuk Lymphoma. 2000 Feb;36(5-6):559-67.
67. Ciolli S, Leoni F, Caporale R, et al. CD34 expression fails to predict the outcome in adult acute myeloid leukemia. Haematoiogica. 1993 May-Jun;78(3): 151-5.
68. Clarkson BD, Boyse EA. Possible explanation of the high concoddance for acute leukaemia in monozygotic twins. Lancet. 1971 Apr 3;1(7701);699-701.
69. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell. 1986 Oct 10;47(1); 19-28.
70. Cohen PL, Hoyer JD, Kurtin PJ, et al. Acute myeloid leukemia with minimal differentiation. A multiple parameter study. Am J Clin Pathol. 1998 Jan;109(l):32-8.
71. Consolini R, Legitime A, Rondelli R, et al. Clinical relevance of CDIO expression in childhood ALL. The Italian Association for Pediatric Hematology and Oncology (AIEOP). Haematoiogica. 1998 Nov;83(Il):967-73.
72. Conter V, Arico M, Valsecchi MG, et al. Intensive BFM chemotherapy for childhood ALL; interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica. Haematoiogica. 1998 Sep;83(9);791-9.
73. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood. 1995 Mar 1;85(5):1151-68.
74. Copplestone JA, Prentice AG. Acute myeloblastic leukaemia in the elderly. Leuk Res. 1988;12(8):617-25.
75. Cordon-Cardo C, Latres E, Drobnjak M, et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994 Feb l;54(3):794-9.
76. Creutzig U, Berthold F, Boos J, et al. Improved treatment results in children with AML: Results of study AML-BFM 93. Klin Padiatr. 2001 Jul;213(4): 175-85.
77. Creutzig U, Harbott J, Sperling C, et al. Clinical significance of surface antigen expression in children with acute myeloid leukemia: results of study AML-BFM-87. Blood. 1995 Oct J5;86(8):3097-i08.
78. Crist W, Boyett J, Pullen J, et al. Clinical and biologic features predict poor prognosis in acute lymphoid leukemias in children and adolescents; a Pediatric Oncology Group review. Med Pediatr Oncol. 1986;I4(3):135-9.
79. Crist W, Shuster J, Look T, et al. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group. Leukemia. I992;6 Suppl 2:162-6.
80. Cross AH, Goorha RM, Nuss R, et al. Acute myeloid leukemia with T-lymphoid features: a distinct biologic and clinical entity. Blood. 1988 Aug;72(2);579-87.
81. Cruse JM, Lewis RE, Pierce S, et al. Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp Mol Pathol. 2005 Aug;79(l):39-41.
82. Cuneo A, Van Orshoven A, Michaux JL, et al. Morphologic, immunologic and cytogenetic studies in ei^throleukaemia: evidence for multilineage involvement and
173
identification of two distinct cytogenetic-clinicopathological types. Br J Haematol. 1990 Jul;75(3);346-54.
83. Dalai BI, Wu V, Barnett MJ, Horsman DE, et al. Induction failure in de novo acute myelogenous leukemia is associated with expression of high levels of CD34 antigen by the leuketnic blasts. Leuk Lymphoma. 1997 Jul;26(3-4):299-306.
84. Darzynkiewicz Z, Bruno S, Del Bino G, et al. Features of apoptotic cells measured by flow cytometry. Cytometry. 1992;13(8):795-808.
85. Datta R, Banach D, Kojima H, et al. Activation of the CPP32 protease in apoptosis induced by 1-beta-D-arabinofuranosylcytosine and other DNA-damaging agents. Blood. 1996 Sep 15;88(6): 1936-43.
86. D'Costa G, Siddiqui HM, Pradhan RM, et al. Pattern of leukemias: a ten-year incidence study of 242 cases. J Postgrad Med. 1989 Oct;35(4): 191-5.
87. de Nuliy Brown F, Jurlander J, Federsen-Bjergaard J, et al. The prognostic significance of chromosomal analysis and immunophenotyping in 1J 7 patients with de novo acute myeloid leukemia. Leuk Res. 1997 Oct;2I(10):985-95.
88. Degos L, Dombret H, Chomienne C, et al. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia. Blood. 1995 May 15;85(10);2643-53.
89. Del Poeta G, Stasi R, Aronica 0, et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood. 1996 Mar 1;87(5): 1997-2004.
90. Del Poeta G, Stasi R, Venditti A, et al. CD7 expression in acute myeloid leukemia. Blood. 1993 Nov 1 ;82(9);2929-30.
91. Del Poeta G, Stasi R, Venditti A, et al. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia. 1994 Mar;8(3):388-94.
92. Del Poeta G, Venditti A, Del Principe MI, et al. Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood. 2003 Mar 15;101(6):2125-31.
93. Delhi cancer registry. Cancer incidence and mortality in Delhi UT urban - 2002 & 2003; Dr. B. R. Ambedkar, Institute of Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi. 2007.
94. den Boer ML, Harms DO, Pieters R, et al. Patient stratification based on prednisolone- vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol. 2003 Sep l;2I(I7):3262-8.
95. den Boer ML, Pieters R, Kazemier KM, et al. Relationship between major vault protein/lung resistance protein, multidriig resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia. Blood. 1998 Mar 15;91(6):2092-8.
96. Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006 Nov 1;107(9):2099-107.
97. Dhooge C, De Moerloose B, Laureys G, et al. P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br J Haematol. 1999 Jun;105(3):676-83.
98. Diaz-Romero J, Vogt G, Weckbecker G. A small-volume technique for simultaneous immunophenotyping and apoptosis detection in rat whole blood by four-color flow cytometry. Cytometry. 2002 Apr l;47(4):265-75.
99. Dordelmann M, Schrappe M, Reiter A, et al. Down’s syndrome in childhood acute lymphoblastic leukemia: clinical characteristics & treatment outcome in four consecutive BFM trials. Berlin-Frankfurt-Miinster Group. Leukemia. 1998 May;12(5);645-51.
100. Drexler HG, Thiel E, Ludwig WD. Acute myeloid leukemias expressing lymphoid- associated antigens: diagnostic incidence and prognostic significance. Leukemia. 1993Apr;7(4):489-98.
174
101. Drexler HG, Thiel E, Ludwig WD. Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. Leukemia. 1991 Aug;5(8):637-45.
102. Dunphy CH. Comprehensive review of adult acute myelogenous leukemia: cytomorphological, enzyme cytocheraica!, flow cytometric immimophenotypic, and cytogenetic findings. J Clin Lab Anal. 1999;13(1): 19-26.
103. Durrant IJ, Richards SM, Prentice HG, et a!. The Medical Research Council trials in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2000 Dec;14(6):1327-52.
104. Ebb DH, Weinstein HJ. Diagnosis and treatment of childhood acute myelogenous leukemia. Pediatr Clin North Am. 1997 Aug;44(4):847-62.
105. Elghetany MT, MacCallum JM, Davey FR.The use of cytochemical procedures in the diagnosis and management of acute and chronic myeloid leukemia. Clin Lab Med.1990 Dec; 10(4):707-20.
106. Ellison RR, Mick R, Cuttner J, et al. The effects of postinduction intensification treatment vi ith cytarabine and daunorubicin in adult acute lymphocytic leukemia: a prospective randomized clinical trial by Cancer and Leukemia Group B. J Clin Oncol. 1991Nov;9(ll):2002-15.
107. El-Sissy AH, El-Mashari MA, Bassuni WY, et al. Aberrant lymphoid antigen expression in acute myeloid leukemia in Saudi Arabia. J Egypt Natl Cane Inst. 2006 Sep;l8(3);244-9.
108. Estey EH. New drugs for therapy of AML Leukemia. 2002 Mar; 16(3);306-9.109. Evans WE, Relling MV, Rodman JH, et al. Conventional compared with individualized
chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998 Feb 19;338(8);499-505.
1 10. Faderl S, Estrov Z. The clinical significance of caspase regulation in acute leukemia. Leuk Lymphoma. 2001 Feb;40(5-6):471-81.
111. Faderl S, Thall PF, Kantarjian HM, et al. Caspase 2 and caspase 3 as predictors of complete remission and survival in adults with acute lymphoblastic leukemia. Clin Cancer Res. 1999 Dec;5(12):4041-7.
112. Fakharzadeh SS, Rosenblum Vos L, Murphy M, et al. Structure and organization of amplified DNA on double minutes containing the mdm2 oncogene. Genomics. 1993 Feb;I5(2):283-90.
113. Feltbower RG, Pearce MS, Dickinson HO, et al. Seasonality of birth for cancer in Northern England, UK. Paediatr Perinat Epidemiol. 2001 Oct;15(4):338-45.
114. Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood. 1999 Aug 15;94(4):l 192-200.
115. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem. 1994 Dec 9;269(49):30761-4.
116. Fialkow PJ, Janssen JW, Bartram CR. Clonal remissions in acute nonlymphocytic leukemia; evidence for a multistep pathogenesis of the malignancy. Blood. 1991 Apr l;77(7):I415-7.
117. Fialkow PJ. Clonal origin of human tumors. Biochim Biophys Acta. 1976 Oct 12;458(3):283-321.
118. Findley HW, Gu L, Yeager AM, et al. Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood. 1997 Apr 15;89{8):2986-93.
119. Finlay CA. The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth. Mol Cell Biol. 1993 Jan;13(l):301-6.
175
!]^!F‘E ^9 iC 'E S
120. Firat H, Favier R, Adam M, et al. Determination of myeloid antigen expression on childhood acute lymphoblastic leukaemia cells: discrepancies using different monoclonal antibody clones. Leuk Lymphoma. 2001 Jun;42(1 -2);75-82.
121. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994 Aug 26;78(4):539-42,
122. Fojo AT, Ueda K, Slamon DJ, et al. Expression of a muitidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA. 1987 Jan;84(l);265-9.
123. Foon KA, Todd RF 3"*. Immunologic classification of leukemia and lymphoma. Blood. 1986 Jul;68(l):l-3I.
124. Freedman DM, Stewart P, Kleinerman RA, et al. Household solvent exposures and childhood acute lymphoblastic leukemia. Am J Public Health. 2001 Apr;91(4):564-7.
125. Fruchart C, Lenormand B, Bastard C, et al. Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia. Am J Hematol. 1996 Nov;53(3); 175-80.
126. Fulda S, Wick W, Weller M, et al. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med. 2002 Aug;8(8);808-15.
127. Galpin AJ, Schuetz JD, Masson E, et al. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity. Mol Pharmacol. 1997 Jul;52(l); 155-63.
128. Gaynon PS, Trigg ME, Heerema NA, et al. Children’s Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia. 2000 Dec;14(l2):2223-33.
129. Geller RB, Zahurak M, Hurwitz CA, et al. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia; the significance of the stem-cell glycoprotein CD34 (My 10). Br J Haematol. 1990 Nov;76(3):340-7.
130. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation- associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984 Oct;133(4):1710-5.
131. Gesbert F, Griffin JD. Bcr/Abl activates transcription of the Bcl-X gene through STATS. Blood. 2000 Sep 15;96(6):2269-76.
132. Ghosh S, Shinde SC, Kuinaran GS, et al, Haematologic and immunophenotypic profile of acute myeloid leukemia: an experience of Tata Memorial Hospital. Indian J Cancer. 2003 Apr-Jun;40(2):71-6.
133. Giona F, Testi AM, Annino L, et al. Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOF experience. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Associazione Italiana Ematologia ed Ocologia Pediatrica. Br J Haematol. 1994 Jan;86(l):55-61.
134. Girod SC, Cesarz D, Fischer U , et al. Detection of p53 and MDM2 protein expression in head and neck carcinogenesis. Anticancer Res. 1995 Jul-Aug; 15(4): 1453-7.
135. Glass DC, Gray CN, Jolley DJ, et al. Leukemia risk associated with low-level benzene exposure. Epidemiology. 2003 Sep;I4(5):569-77.
136. Gleissner B, Goekbuget N, Rieder H, et al. CD 10- pre-B acute lymphoblastic leukemia (ALL) is a distinct high-risk subgroup of adult ALL associated with a high frequency of MLL aberrations: results of the German Multicenter Trials for Adult ALL (GMALL). Blood. 2005 Dec I5;106(13):4054-6.
137. Goker E, Waltham M, Kheradpour A, et al. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood. 1995 Jul 15;86(2):677-84.
138. Greaves M. Childhood leukaemia. BMJ. 2002 Feb 2;324(7332):283-7.139. Greaves MF, Alexander FE. An infectious etiology for common acute lymphoblastic
leukemia in childhood? Leukemia. 1993 Mar;7(3):349-60.
176
140. Greaves MF, Maia AT, Wiemels JL, et al. Leukemia in twins: lessons in natural history. Blood. 2003 Oct l;l02(7);232l-33.
141. Greaves MF. Speculations on the cause of childhood acute lymphoblastic leukemia. Leukemia. 1988 Feb;2(2); 120-5.
142. Greenland S, Sheppard AR, Kaune WT, et al. A pooled analysis of magnetic fields, wire codes, and childhood leukemia. Childhood Leukemia-EMF Study Group. Epidemiology. 2000Nov;ll(6);624-34.
143. Griffin JD, Davis R, Nelson DA, et al. Use of surface marker analysis to predict outcome of adult acute myeioblastic leukemia. Blood. 1986 Dec;68(6); 1232-41.
144. Gross L. Viral etiology of cancer and leukemia; a look into the past, present and future G.H.A. Clowes Memorial Lecture. Cancer Res. 1978 Mar;38(3);485-93.
145. Grossman J. What’s hiding under the sink: dangers of household pesticides. Environ Health Perspect. 1995 Jun;103(6):550-4.
146. Guo Y, Yang K, Harwalkar J, et al. Phosphoiylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene. 2005 Apr 14;24(16):2599-612.
147. Haase D, Feuring-Buske M, Konemann S, et al. Evidence for malignant transfonnation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+subpopulations. Blood. 1995 Oct 15;86(8):2906-i2.
148. Haber DA. Multidrug resistance (MDR 1) in leukemia: is it time to test? Blood. 1992 Jan l5;79(2):295-8.
149. Haferlach T, Kohlmann A, Kern W, et al. Gene expression profiling as a tool for the diagnosis of acute leukemias. Semin Hematol. 2(K)3 Oct;40(4);28I-95.
150. Hainaut P. The tumor suppressor protein p53; a receptor to genotoxic stress that controls cell growth and survival. Curr Opin Oncol. 1995 Jan;7(l):76-82.
151. Haidar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA. 1995 May 9;92(10):4507-11.
152. Hammami A, Chan WC, Michels SD, et al. Mature B-cell acute leukemia: a clinical, morphological, immunological, and cytogenetic study of nine cases. Hematol Pathol. 1991;5(3);109-18.
153. Hann IM, Richards SM, Eden OB, et al. Analysis of the immunophenotype of children treated on the Medical Research Council United Kingdom Acute Lymphoblastic Leukaemia Trial XI (MRC UKALLXI). Medical Research Council Childhood Leukaemia Working Party. Leukemia. 1998 Aug; 12(8): 1249-55.
154. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood. 1997 Mar 15;89(6);1845-53.
155. Hanson CA, Abaza M, Sheldon S, et al. Acute biphenotypic leukaemia; immunophenotypic and cytogenetic analysis. BrJ Haematol. 1993 May;84(I):49-60.
156. Harris 1^, Jaffa ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms; a proposal from the International Lymphoma Study Group. Blood. 1994 Sep 1;84(5): 1361-92.
157. Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999 Nov;17(ll):3569-76.
158. Hockenbery D, Nunez G, Milliman C, et al. BcI-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990 Nov 22;348(6299);334-6.
159. Hockenbery DM, Oltvai ZN, Yin XM, et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell. 1993 Oct 22;75(2):241-51.
160. Hoelzer DF. Therapy of the newly diagnosed adult with acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 1993 Feb;7(l):I39-60.
161. Hoffbrand AV, Moss PAH, and Pettit IE. Essential Haematology (5* ed.), Blackwell. 2006.
162. Hogarth LA, Hall AG, Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphocytic leukemia. Blood. 1999 Apr 15;93(8):2671-8.
177
^ ^ ‘E ^ 9 iC ‘ES
163. Holleman A, den Boer ML, de Menezes RX, et al. The expression of 70 apoptosis genes in relation to lineage, genetic subtype, cellular drug resistance, and outcome in childhood acute lymphoblastic leukemia. Blood. 2006 Jan 15;107(2):769-76.
164. Hollstein M, Hergenhahn M, Yang Q, et al. New approaches to understanding p53 gene tumor mutation spectra. MutatRes. 1999 Dec 17;431(2):199-209.
165. Hongo T, Yajima S, Sakurai M, et al. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia. Blood.1997 Apr 15;89(8):2959-65.
166. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-perox idase complex (ABC) in iramunoperoxidase techniques: a comparison between ABC and uniabeled antibody (PAP) procedures.! Histochem Cytochem. 1981 Apr;29(4):577-80.
167. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 1988 Aug;72(2):567-72.
168. Huh YO, Ibrahim S. Immunophenotypes in adult acute lymphocytic leukemia. Role of flow cytometry in diagnosis and monitoring of disease. Hematol Oncol Clin North Am. 2000Dec;14(6):1251-65.
169. Ibrado AM, Huang Y, Fang G, et al. Overexpression of Bcl-2 or Bcl-xL inhibits Ara-C- induced CPP32/Yama protease activity and apoptosis of human acute myelogenous leukemia HL-60 cells. Cancer Res. 1996 Oct 15;56(20):4743-8.
170. Infante-Rivard C, Deadman JE. Maternal occupational exposure to extremely low frequency magnetic fields during pregnancy and childhood leukemia. Epidemiology. 2003 Jul;14(4):437-41.
171. Infante-Rivard C, Guiguet M. Family history of hematopoietic and other cancers in children with acute lymphoblastic leukemia. Cancer Detect Prev. 2004;28(2):83-7.
172. Invernizzi R, Pecci A, Bellotti L, et al. Expression of p53, bcl-2 and ras oncoproteins and apoptosis levels in acute leukaemias and myelodysplastic syndromes. Leuk Lymphoma. 2001 Jul;42(3):481-9.
173. Jaffe ES, Harris NL, Stein H, Vardiman JW, (eds). World Health Organization Classification of Tumors: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: lARC Press; 2001.
174. Jaroslav P, Martina H, Jiri S, et al. Expression of cyclins Dl, D2, and D3 and Ki-67 in Leukemia. Leuk Lymphoma. 2005 Nov;46(l 1):1605-1612.
175. Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood. 1997 Oct 15;90(8):2863-92.
176. Jensen AW, Hokland M, Jorgensen H, et al. Solitary expression of CD7 among T-cell antigens in acute myeloid leukemia: identification of a group of patients with similar T- cell receptor beta and delta rearrangements and course of disease suggestive of poor prognosis. Blood. 1991 Sep I ;78(5): 1292-300.
177. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002 Jan 25;108(2): 153-64.
178. Joza N, Susin SA, et al. Essential role of the mitochondria! apoptosis-inducing factor in programmed cell death. Nature. 2001Mar 29;410(6828):549-54.
179. Jussawalla DJ, Yeole BB. Childhood cancers in greater Bombay (1973-1984). Indian J Cancer. 1988 Dec;25(4): 197-206.
180. Kamat DM, Gopal R, Advani SH, et al. Pattern of subtypes of acute lymphoblastic leukemia in India. Leuk Res. 1985;9(7):927-34.
181. Kamel AM, Assem MM, Jaffe ES, et al. Immunological phenotypic pattern of acute lymphoblastic leukaemia in Egypt. Leuk Res. 1989;13(7):519-25.
182. Kanerva J, Tiirikainen MI, Makipemaa A, et al. Initial P-glycoprotein expression in childhood acute lymphoblastic leukemia: no evidence of prognostic impact in follow- up. Pediatr Hematol Oncol. 2001 Jan-Feb;I8(I):27-36.
178
183. Karakas T, Maurer U, Weidmann E, et al. High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol. 1998 Feb;9(2): 159-65.
184. Kaspers GJ, Kardos G, Pieters R, et al. Different cellular drug resistance profiles in childhood lymphoblastic and non-lymphoblastic leukemia: a preliminary report. Leukemia. 1994 Jul;8(7): 1224-9.
185. Kaspers GJ, Veemian AJ, Pieters R, et al. In vitro cellular drug resistance and prognosis in newly diagnosed childhood acute lymphoblastic leukemia. Blood. 1997 Oct l;90(7);2723-9.
186. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991 Dec 1;51(23 Pt 1);6304-11.
187. Kawai S, Zha Z, Yamamoto Y, et al. Clinical significance of childhood acute myeioid leukemias expressing lymphoid-associated antigens. Pediatr Hematol Oncol. 1995 Sep- Oct;12(5):463-9.
188. Kawamura M, Ohnishi H, Guo SX, et al. Alterations of the p53, p21, p l6, pl5 and RAS genes in childhood T-cell acute lymphoblastic leukemia. Leuk Res. 1999 Feb;23(2): 115-26.
189. Kearns P, Pieters R, Rottier MM, et al. Glutathione in childhood acute leukaemias. Adv Exp Med Biol. 1999;457:211-6.
190. Kelman Z. PCNA: structure, functions and interactions. Oncogene. 1997 Feb 13;14(6):629-40.
191. Kern W, Haferlach T, Schoch C, et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood. 2003 Jan 1;101(1):64-70.
192. Kerr JF, Wyllie AH, et al. Apoptosis: a basic biological phenomenon with wide- ranging implications in tissue kinetics. Br J Cancer. 1972 Aug;26(4);239-57.
193. Khalidi HS, Chang KL, Medeiros LJ, et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol. 1999 Apr;l 11(4):467-76.
194. Khalidi HS, Medeiros LJ, Chang KL, et al. The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and kaiyotypic abnormalities. Am J Clin Pathol. 1998 Feb;109(2):211-20.
195. Khawaja MR, Allana SS, Akbarali AN, et al. Flow cytometric and demographic analysis of t cell acute lymphoblastic leukemia in Pakistani population. J Ayub Med Coil Abbottabad. 2005 Oct-Dec;17(4):3-8.
196. Killick S, Matutes E, Powles RL, et al. Outcome of biphenotypic acute leukemia. Haeniatologica. 1999 Aug;84(8):699-706.
197. Kinney CM, Lukens JN. Classification and differentiation of acute leukemias. In: Wintrobe’s Clinical Hematology (10* eds). Lee RG, Forester J, Bithell TC et al. (eds), Williams and Wilkins, USA; 1998. 2209-2211.
198. Kita K, Miwa H, Nakase K, et al. Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma. Blood.1993 May l;8I(9):2399-405.
199. Kita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;2 1 )(q2 2 ;q2 2 ) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood. 1992 Jul 15;80(2):470-7.
200. Kleinerman RA, Kaune WT, Hatch EE, et al. Are children living near high-voltage power lines at increased risk of acute lymphoblastic leukemia? Am J Epidemiol. 2000 Mar 1; 151 (5):512-5.
179
^ICE^F'E^^CES
201. Kluck RM, Bossy-Wetzel E, Green DR, et a!. The release of cytochrome c from mitochondria; a primary site for Bcl-2 regulation of apoptosis. Science. 1997 Feb 21:275(5303); 1132-6.
202. Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, Hahlen K, et al. In vitro cellular drug resistance in children with relapsed/refractory acute lymphoblastic leukemia. Blood. 1995 Nov 15;86(10);3861-8.
203. Konopleva M, Zhao S, Hu W , et al. The anti-apoptotic genes BcI-X(L) and Bcl-2 are over-expressed and contribute to chemoresistance of non-proliferating leukaemic CD34+ cells. Br J Haematol 2002 Aug; 118(2);521-34
204. Komblau SM. The role of apoptosis in the pathogenesis, prognosis, and therapy of hematologic malignancies. Leukemia. 1998 Sep;12 Suppl l;S41-6.
205. Kotylo PK, Seo IS, Smith FO, et al. Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-MO). Am J Clin Pathol. 2000 Feb; 113(2); 193-200.
206. Krajewski S, Tanaka S, Takayama S, et al. Investigation of the subcelluiar distribution of the bcl-2 oncoprotein; residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. Cancer Res, 1993 Oct I;53(19);4701-14.
207. Krajincvic M, Labuda D, Sinnetl D. Glutathione S~transferase PI genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukaemia. Pharmacogenetics. 2002 Nov;12(8);655-8.
208. Krause JR, Penchansky L, Contis L, et al. Flow cytometry in the diagnosis of acute leukemia. Am J Clin Pathol. 1988 Mar;89(3);341-6.
209. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nat Med. 1997Jun;3(6);614-20.
210. Kuerbitz SJ, Civin C l , Krischer JP, et al. Expression of myeloid-associated and lymphoid-associated cell-surface antigens in acute myeloid leukemia of childhood: a Pediatric Oncology Group study. J Clin Oncol. 1992 Sep; 10(9); 1419-29.
211. Kumar S, Harvey NL. Role of multiple cellular proteases in the execution of programmed cell death. FEES Lett. 1995 Nov 20;375(3); 169-73.
212. Kushwaha MR, Chandra D, Misra NC, et al. Leukaemias and lymphomas at Lucknow, India. LeukRes. 1985;9(6);799-802.
213. Kussie PH, Gorina S, Marechal V, et al. Structure of the MDM2 oncoprotein bound to thep53 tumor suppressor transactivation domain. Science. 1996 Nov 8;274(5289);948-53.
214. Kyoda K, Nakamura S, Hattori N, et al. Lack of prognostic significance of CD34 expression in adult AML when FAB MO and M3 are excluded. Am J Hematol. 1998 Mar;57(3);265-6.
215. La Russa VF, Griffin JD, Kessler SW, et al. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro heraatopoiesis in long-term marrow cultures. Exp Hematol. 1992 May;20(4);442-8.
216. LaBaer J, Garrett MD, Stevenson LF, et al. New functional activities for the p21 family of CDK inhibitors. Genes Dev. 1997 Apr 1 ;11(7);847-62.
217. Laerum OD, Bjerknes R, (eds). Flow Cytometry in Hematology. Academic Press Limited, London, San Diego, 1992, Academic Press, 1992.
218. Lamy T, Goasguen IE, Mordelet E, et al. P-glycoprotein (P-I70) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia. 1994 Nov;8(l 1); 1879-83.
219. Lanza F, Rigolin GM, Moretti S, et al. Prognostic value of immunophenotypic characteristics of blast cells in acute myeloid leukemia. Leuk Lymphoma. 1994; 13 Suppl l;81-5.
220. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995 Apr 15;85(8);2025-37.
180
221. Larson RA, Dodge RK, Linker CA, et al. A randomized controiled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 91IL Blood. 1998 Sep 1;92(5):1556-64.
222. Laupeze B, Amiot L, Drenou B, et al. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol. 2002 Mar; 116(4);834-8.
223. Lauria F, Raspadori D, Martinelli G, et al. Increased expression of myeloid antigen markers in adult acute lymphoblastic leukaemia patients; diagnostic and prognostic implications. BrJ Haematol. 1994 Jun;87(2);286-92.
224. Lauria F, Raspadori D, Rondelli D, et al. High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate. Leukemia.1997 Dec;ll(12):2075-8.
225. Lauria F, Raspadori D, Ventura MA, et a!. CD7 expression does not affect the prognosis in acute myeloid leukemia. Blood. 1994 May 15;83(10):3097-8.
226. Le QH, Thomas X, Ecochard R, et al. Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia. Eur J Haematol. 2006 Dec;77(6):471- 9.
227. Lee EJ, Yang J, Leavitt RD, et al. The significance of CD34 and TdT determinations in patients with untreated de novo acute myeloid leukemia. Leukemia. 1992 Nov;6( 11): 1203-9.
228. Lee S, Eienbaas B, Levine A, et al. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell. 1995 Jun 30;81(7); 1013-20.
229. Legrand O, Perrot JY, Baudard M, et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood. 2000 Aug 1;96(3):870- 7,
230. Legrand O, Simonin G, Perrot .TY, et al. Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood. 1998 Jun 15;91(12);4480-8.
231. Leith CP, Kopecky KJ, Chen M , et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDRl/P-giycoprotein, MRPl, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood. 1999 Aug 1;94(3); 1086-99.
232. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDRl) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997 May l;89(9):3323-9.
233. Lewis RE, Cruse JM, Sanders CM, et al. Aberrant expression of T-cell markers in acute myeloid leukemia. Exp Moi Pathol. 2007 Dec;83(3):462-3.
234. Li H, Wang Y, Lou F. [Expression of cyclin D1 mRNA in acute leukemia patients and its clinical implication] Zhonghua Xue Ye Xue Za Zhi. 1999 Jul;20(7);357-8.
235. Li X, Gong J, Feldman E, et al. Apoptotic cell death during treatment of leukemias. Leuk Lymphoma. 1994;I3 Supp! 1:65-70.
236. Lin CW, Manshouri T, Jilani I, et al. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res. 2002 Jun;26(6):551-9.
237. Linet MS, Hatch EE, Kleinerman RA, et al. Residential exposure to magnetic fields and acute lymphoblastic leukemia in children. N Engl J Med. 1997 Jul 3;337(l):I-7.
238. List AF, Kopecky KJ, Willman CL, et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2001 Dec 1;98(12):3212-20.
239. Liu YR, Wang YZ, Chen SS, et al. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia] Zhonghua Xue Ye Xue Za Zhi. 2007 Nov;28(l l):731-6.
181
240. Lo Coco F, De Rossi G, Pasqualetti D, et al. CD7 positive acute myeloid leukaemia: a subtype associated with cell immaturity. Br J Haematol 1989 Dec;73(4):480-5.
241. Lowe SW, Riiley HE, Jacks T, et al. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 1993 Sep 24;74(6):957-67.
242. Lowenberg B, van Putten WL, Touw BP, et al. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med. 1993 Mar4;328(9);614-9.
243. Lowengart RA, Peters JM, Cicioni C, et ai. Childhood leukemia and parents’ occupational and home exposures. J Nat! Cancer Inst. 1987 Jul;79(I):39-46.
244. Macedo A, Orfao A, Vidriales MB, et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann Hematol. 1995 Apr70(4): 189-94.
245. Macnamara B, Palucka KA, Porwit-MacDonald A. Balance between proliferation and apoptosis in leukemic cell lines resistant to cytostatics. Leuk Lymphoma. 1999 Dec;36(I-2):179-89.
246. Mahoney MC, Moysich KB, McCarthy PL Jr, et al. The Chernobyl childhood leukemia study; background & lessons learned. Environ Health. 2004 Nov 8;3(1);12.
247. Malayeri R, Filipits M, Suchomel RW, et al. Multidrug resistance in leukemias and its reversal. Leuk Lymphoma. 1996 Nov;23(5-6):451-8.
248. Margolin JF and Poplack DG. Acute Lymphoblastic Leukemia In: Principles and Practice in Pediatric Oncology. Pizzo P and Poplack D (eds), J. B. Lippincott Company. Philadelphia and New York. 1997:409-462
249. Martin SJ, Green DR. Protease activation during apoptosis: death by a thousand cuts? Cell. 1995 Aug ll;82(3):349-52.
250. Matheriy LH, Taub JW, Wong SC, et al. Increased frequency of expression of elevated dihydrofolate reductase in T-cell versus B-precursor acute lymphoblastic leukemia in children. Blood. 1997 Jul 15;90(2):578-89.
251. Matsubara K, Kubota M, Adachi S, et al. Induction of apoptosis in childhood acute leukemia by chemotherapeutic agents: failure to detect evidence of apoptosis in vivo. Eur J Haematol. 1994 Jan;52(l):47-52.
252. Matutes E, Catovsky D. The value of scoring systems for the diagnosis of biphenotypic leukemia and mature B-cell disorders. Leuk Lymphoma. 1994; 13 Suppl 1:11-4.
253. Matutes E, Morilla R, Farahat N, et aJ. Definition of acute biphenotypic leukemia. Haematologica. 1997 Jan-Feb;82(l):64-6.
254. Mauer AM. Therapy of acute lymphoblastic leukemia in childhood. Blood. 1980 Jul;56(l):l-10.
255. Maung ZT, MacLean ER, Reid MM, et al. The relationship between bcI-2 expression and response to chemotherapy in acute leukaemia. BrJ Haematol. 1994 Sep;88(l):I05- 9.
256. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med. 1994 Oct 6;331(14):896-903.
257. Mi Y, Bian S, Chen G. [Study on the expression of myeloid markers and CD34 antigen in adult acute lymphoblastic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 1999 Feb;20(2):76-8
258. Miller KB, Daonst PR. Clinical Manifestation of Acute Myeloid Leukemia. In; Haematology Basic Principles and Practice. (3' ‘‘ edn). Hoffman R, et al (eds) Pennsylvania; Churchill Livingstone: 2000.
259. Miller RW. Persons with exceptionally high risk of leukemia. Cancer Res. 1967 Dec;27(12);2420-3.
260. Miller RW. Relation between cancer and congenital defects: an epidemiologic evaluation. J Natl Cancer Inst. 1968 May;40(5): 1079-85.
261. Morgan GJ, Shiach C, Potter M. The clinical value of detecting gene rearrangements in acute leukaemias. BrJ Haematol. 1994 Nov;88(3):459-64.
182
262. Moriai R, Asanuma K, Kobayashi D, et al. Quantitative analysis of the anti-apoptotic gene survivin expression in malignant haematopoietic cells. Anticancer Res. 2001 Jan- Feb;21(lB);595-600.
263. Muller-Ticlow C, Schwable J, Steffen B, et al. High-throughput analysis of genome- wide receptor tyrosine kinase expression in human cancers identifies potential novel drug targets. Clin Cancer Res. 2004 Feb 15;10(4):1241-9.
264. Myers A, Clayden AD, Cartwright RA, et ai. Childhood cancer and overhead pou'erlines: a case-control study. Br J Cancer. 1990 Dec;62(6):1008-14.
265. Nachman J, Sather HN, Buckley JD, et al. Young adults 16-21 years of age at diagnosis entered on Childrens Cancer Group acute lymphoblastic leukemia and acute myeloblastic leukemia protocols. Results of treatment. Cancer. 1993 May 15;71(10 Suppl):3377-85.
266. National Cancer Registry Programme. Consolidated report of the population based cancer registries 1990-1996; Incidence and distribution of cancer. Indian Council of Medical Research, New Delhi. 2001.
267. Naumovski L, Martinovsky G, Wong C, et al. BCL-2 expression does not coixelate with patient outcome in pediatric acute myelogenous leukemia. Leuk Res. 1998 Jan;22(!):81-7.
268. Ng SM, Ariffin WA, Lin HP, et al. Clinical features and treatment outcome of children with myeloid antigen coexpression in B-lineage acute lymphoblastic leukemiara study of 151 Malaysian children. J Trop Pediatr. 2000 Apr46(2);73-8.
269. Nicholson DW, Ali A, Thomberry NA, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 1995 Jul 6;376 (6535):37-43.
270. Norgaard JM, Jensen PD, Bendix K, et al. Relevance of in vitro leukaemia cell survival to short- and long term clinical outcome in AML. Leuk Lymphoma. 1999 Jan;32(3- 4):327-37.
271. Norgaard JM, Langkjer ST, Palshof T, et al. Relation of blast cell survival and proliferation to chemotherapy resistance in AML. Br J Haematol. 1996 Jun;93(4);888-97.
272. Norgaard JM, Langkjer ST, Palshof T, et al. Pretreatment leukaemia cell drug resistance is correlated to clinical outcome in acute myeloid leukaemia. Eur J Haematol. 2001 Mar;66(3): 160-7.
273. Nucifora G, Rowley JD. AMLl and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood. 1995 Jul 1;86(1):1-14.
274. O’Brien TA, Russell SI, Vowels MR, et al. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children’s Cancer Study Group. Blood. 2002 Oct 15;100(8):2708-16.
275. O’Connor SM, Boneva RS. Infectious etiologies of childhood leukemia: plausibility and challenges to proof. Environ Health Perspect. 2007 Jan;l 15(l):146-50.
276. Oliner JD, Kinzler KW, Meltzer PS, et ai. Amplification of a gene encoding a p53- associated protein in human sarcomas. Nature. 1992 Jul 2;358(638I);80-3.
277. Oliver L, Vavasseur F, Mahe B, et al. Assessment of caspase activity as a possible prognostic factor in acute myeloid leukaemia. Br J Haematol. 2002 Aug;l 18(2):434-7.
278. Ong YL, McMulHn MF, Bailie KE, et al. High bax expression is a good prognostic indicator in acute myeloid leukaemia. Br J Haematol. 2000 Oct;111(1): 182-9.
279. Orfao A, Ruiz-Arguelles A. Citometria de flisjo y su apHcacion en Hematologia. In: Lopez Borrasca A, Arocha Pirango C, Campos Guerra C, Parreira A, Pavlovsky S, Ruiz-Arguelles G. San Miguel JF, (eds). Enciclopedia de Hematologia Iberoamericana. Universidad de Salamanca, 1993:161-75.
280. Orfao A, Vidriales B, Gonzalez M, et al. Diagnostic and prognostic importance of immunophenotyping in adults with acute myeloid leukemia. In: Ludwig WD, Thiel E, (eds). Recent results in cancer research: recent advances in cell biology of acute
183
leukemias. Impact on clinical diagnosis and therapy. Berlin:Sprlnger-Verlag, 1993:369-79.
281. Ornierod MG. The study of apoptotic cells by flow cytometry. Leukemia. 1998 Jul;12(7):10I3-25.
282. Padmanjali KS, Gupta S, Toraar S, et al. Relapse pattern of acute lymphoblastic leukemia in children treated on an uniform regimen and analysis of risk factors. Indian JPediatr2002;69:S2-S8.
283. Paietta E, Andersen J, Yunis J, et al. Acute myeloid leukaemia expressing the leucocyte integrin CDllb-a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis. Eastern Cooperative Oncology Group. Br J Haematol. 1998 Feb;100(2);265-72.
284. Pallis M, Turzanski J, Grundy M, et al. Resistance to spontaneous apoptosis in acute myeloid leukaemia blasts is associated with p-glycoprotein expression and function, but not with the presence of FLT3 internal tandem duplications. Br J Haematol. 2003 Mar;120(6):1009-16.
285. Parkin DM et al (eds). Cancer Incidence in Five Continents, Vol. VII Lyon, International Agency for Research on Cancer, (L\RC Scientific Publication). 1997 (143).
286. Pellet S, Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum Mutat. 2003 Mar,21(3):277-84.
287. Pestell RG, Albanese C, Reutens AT, et al. The cyclins and eye tin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev. 1999 Aug;20(4):501-34.
288. Pierce M. Childhood leukemia. J Pediatr. 1936(8): 66-95.289. Pieters R, Loonen AH, Huismans DR, et al. In vitro drug sensitivity of cells from
children with leukemia using the MTT assay with improved culture conditions. Blood. 1990Dec l;76(ll):2327-36.
290. Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia— implications for treatment of infants. Leukemia. 1998 Sep;12(9):1344-8.
291. Pieters R, Huismans DR, Loonen AH, et al. Relation of cellular drug resistance to longterm clinical outcome in childhood acute lymphoblastic leukaemia. Lancet. 1991 Aug 17;338(8764):399-403.
292. Pieters R, Klumper E, Kaspers GJ, et al. Everything you always wanted to know about cellular drug resistance in childhood acute lymphoblastic leukemia. Crit Rev Oncol Hematol. 1997 Jan;25(l): 11-26.
293. Pirker R, Wallner J, Geissler K, et al. MDRI gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst. 1991 May 15;83(10):708-12.
294. Pisani P, Parkin DM, Ferlay J. Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer. 1993 Dec 2;55(6):89l-903.
295. Pituch-Noworolska A. Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children.] Folia Med Cracov. 2001;42(3):5-80.
296. Porwit-MacDonald A, Janossy G, Ivory K, et al. Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood. 1996 Feb l;87(3):lI62-9.
297. Posovszky C, Friesen C, Herr 1, et al. Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis. Leukemia. 1999 Mar;l3(3);400-9.
298. Prakash S, Ramamurthi, Gopalan R, et al. Leukaemias at Pondicherry, Indian J Cancer. 1981 Mar; 18(1): 1-6.
184
299. Praxedes MK, De Oliveira LZ, Pereira Wda V, et al. Monoclonal antibody anti-MPO is useful in recognizing minimally differentiated acute myeloid leukaemia. Leuk Lymphoma. 1994 Jan;12(3-4);233-9.
300. Preti HA, Huh YO, O’Brien SM, et al. Myeloid markers in adult acute lymphocytic leukemia. Correlations with patient and disease characteristics and with prognosis. Cancer. 1995 Nov 1;76(9): 1564-70.
301. Prokop A, Wieder T, Sturm I, et al. Relapse in childhood acute lymphoblastic leukemia is associated with a decrease of the Baxy^cl-2 ratio and loss of spontaneous caspase-3 processing in vivo. Leukemia. 2000 Sep; 14(9): 1606-13.
302. Pui CH, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. Blood. 1993 Jul 15;82(2):343-62.
303. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11,12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children’s Research Hospital. Leukemia. 2000Dec;14(12):2286-94.
304. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998 Aug 27;339(9);605-15.
305. Pui CH, Hancock ML, Head DR, et al. Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. Blood. 1993 Aug l;82(3):889-94.
306. Pui CH, Raimondi SC, Head DR, et al. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood. 1991 Sep 1;78(5); 1327-37.
307. Pui CH, Rivera GK, Hancock ML, et al. Clinical significance of CD 10 expression in childhood ALL. Leukemia. 1993 Jan;7(l):35-40.
308. Pui CH, Sandlund JT, Pei D, et al. Results of therapy for acute lymphoblastic leukemia in black and white children. JAMA. 2003 Oct 15;290(I5);2001-7.
309. Pui CH, Schell MJ, Raimondi DR, et al. Myeloid-antigen expression in childhood acute lymphoblastic leukemia. N EnglJ Med. 1991 Nov 7;325(19): 1378-82.
310. Pui CH, Williams DL, Raimondi SC, et al. Unfavorable presenting clinical and laboratory features are associated with CALLA-negative non-T, non-B lymphoblastic leukemia in children. Leuk Res. 1986; 10(11).T 287-92.
311. Pui CH. Childhood leukemias. N Engl J Med. 1995 Jun 15;332(24): 1618-30.312. Pullen J, Shuster JJ, Link M, et al. Significance of commonly used prognostic factors
differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor ALL. A Pediatric Oncology Group (FOG) study. Leukemia. 1999Nov;13(ll);1696-707.
313. Rajalekshmy KR, Abitha AR, Pramila R, et al. Immunophenotypic analysis of T-cell acute lymphoblastic leukaemia in Madras, India. Leuk Res. 1997 Feb;21(2); 119-24.
314. Rani S, Beohar PC, Mohanty TK, et al. Leukaemic pattern in Delhi-a ten year study of 490 cases. Indian J Cancer. 1982 May-Jun;19(2):81-6.
315. Raspadori D, Lauria F, Ventura MA, et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Leuk Res. 1997 Jul;21(7):603-7.
316. Reading CL, Estey EH, Huh YO, et al. Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood. 1993 Jun l;81(ll):3083-90.
317. Reed JC. Bcl-2 family proteins. Oncogene. 1998 Dec 24;17(25);3225-36.318. Reid MM, Proctor SJ, Failure of FAB classification to predict relapse-free survival in
acute leukemia. Lancet. 1982 Jul 17;2(8290): 153-4.319. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood
acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood. 1994 Nov l;84(9):3I22-33.
320. Reiter A, Schrappe M, Ludwig WD, et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood. 1992 Nov 15;80(10):2471-8.
185
321. Reynisdottir I, Massague J. The subcellular locations of pl5(Ink4b) and p27(Kipl) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 1997 Feb 15;ll(4);492-503.
322. Rinsky RA, Young RJ, Smith AB. Leukemia in benzene workers. Am J Ind Med. 1981;2(3):217-45.
323. Robak T. Acute lymphoblastic leukaemia in elderly patients: biological characteristics and therapeutic approaches. Drugs Aging. 2004;21(12):779-91.
324. Roberts GT, Spence DG, Padmos MA, et al. Morphologic iminunophenotypic and cytogenetic patterns of adult acute myeloid leukemia in Saudi Arabia. Leuk Res. 1992; 16(2): 181-90.
325. Robison LL, Buckley JD, Daigle AE, et al. Maternal drug use and risk of childhood nonlymphoblastic leukemia among offspring. An epidemiologic investigation implicating marijuana (a report from the Childrens Cancer Study Group). Cancer. 1989 May 15;63(10):1904-ll.
326. Robison LL, Neglia JP. Epidemiology of Down syndrome and childhood acute leukemia. Prog Clin Biol Res. I987;246:19-32.
327. Romana SP, Poirel H, Leconiat M, et al. High frequency of t(12;21) in childhood B- lineage acute lymphoblastic leukemia. Blood. 1995 Dec l;86(ll);4263-9.
328. Ron E. Ionizing radiation and cancer risk; evidence from epidemiology. Radial Res.1998 Nov;150(5 Suppl):S30-4L
329. Ross JA, Potter JD, Reaman GH, et al. Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States); a report from the Children’s Cancer Group, Cancer Causes Control. 1996 Nov;7(6):581-90.
330. Ross JA, Severson RK, Swensen AR, et al. Seasonal variations in the diagnosis of childhood cancer in the United States. Br J Cancer, 1999 Oct;81(3):549-53.
331. Rothe G, Schmitz G. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. Leukemia. 1996 May;10(5):877-95.
332. Rots MG, Zwaan CM, Pieters R, et al. Continuous exposure to methotrexate overcomes resistance in childhood acute myeloid leukemia in vitro [abstract], Pediatr Res. 1999;45:775.
333. Rovelli A, Biondi A, Cantu Rajnoldi A, et al. Microgranular variant of acute promyelocytic leukemia in children. J Clin Oncol. 1992 Sep;10(9):1413-8.
334. Rowe D, Devaraj PE, Irving JA, et al. A case of mature B-cell ALL with coexistence of t(l;19) and t(14;18) and expression of the E2A/PBX1 fusion gene, Br J Haematol, 1996 Jul;94(l);I33-5.
335. Rubnitz JE, Downing JR, Pui CH, et al. TEL gene rearrangement in acute lymphoblastic leukemia; a new genetic marker with prognostic significance. J Clin Oncol. 1997 Mar; 15(3):1150-7.
336. Rushton L, Romaniuk H. A case-control study to investigate the risk of leukaemia associated with exposure to benzene in petroleum marketing and distribution workers in the United Kingdom. Occup Environ Med. 1997 Mar;54(3): 152-66.
337. Saad E, et al. Markers of tumor cell proliferative activity. In book: Tumor markers.1998 Chapter-1 1 .
338. Sachs L, Lotem J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood. 1993 Jul 1;82(1):15-2I.
339. Sali D, Cardis E, Sztanyik L, et al. Cancer consequences of the Chernobyl accident in Europe outside the former USSR: a review. Int J Cancer. 1996 Jul 29;67(3):343-52.
340. Salomons GS, Smets LA, Verwijs-Janssen M, et al. Bcl-2 family members in childhood acute lymphoblastic leukemia; relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome. Leukemia, 1999 Oct; 13(10): 1574-80.
186
341. Samdani A, Vijapurkar U, Grimm MA, et al. Cytogenetics and P-glycoprotein (PGP) are independent predictors of treatment outcome in acute myeloid leukemia (AML). LeukRes. 1996 Feb;20(2): 175-80.
342. San Miguel JF, Gonzalez M, Canizo MC, et al. Leukemias with megakaryoblastic involvement; clinical, hematologic, and immunologic characteristics. Blood. 1988 Aug;72(2):402-7.
343. San Miguel JF, Hernandez JM, Gonzalez-Samiiento R, et al. Acute leukemia after a primary myelodysplastic syndrome; immunophenotypic, genotypic, and clinical characteristics. Blood. 1991 Aug l;78(3);768-74.
344. Sather HN. Age at diagnosis in childhood acute lymphoblastic leukemia. Med Pediatr Oncoi. 1986;14(3);166-72.
345. Sauerbrey A, ZintI F, Volm M. P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia. Br J Cancer. 1994 Dec;70(6): 1144-9.
346. Savitskiy VP, Shman TV, Potapnev MP. Comparative measurement of spontaneous apoptosis in pediatric acute leukemia by different techniques. Cytometry B Clin Cytom. 2003 Nov;56(l); 16-22.
347. Saxena A, Sheridan DP, Card RT, et al. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am J Hematol. 1998 Aug;58(4);278-84.
348. Schimmer AD, Hediey DW, Penn LZ, et al. Receptor- and mitochondrial-mediated apoptosis in acute leukemia: a translational view. Blood. 2001 Dec 15;98(13):3541-53.
349. Schlessinger J.Cel! signaling by receptor tyrosine kinases. Cell. 2000 Oct 13;103(2);211-25.
350. Schmid I, Uittenbogaart CH, Keld B, et al. A rapid method for measuring apoptosis and dual-color immunofluorescence by single laser flow cytometry. J Immunol Methods. 1994 Apr 15;170(2); 145-57.
351. Schmiegelow K, Nyvold C, Seyfarth J, et al. Post-induction residual leukemia in childhood acute lymphoblastic leukemia quantified by PCR correlates with in vitro prednisolone resistance. Leukemia. 2001 Jul;15(7):1066-71.
352. Schorin MA, Blattner S, Gelber RD, et al. Treatment of childhood acute lymphoblastic leukemia; results of Dana-Farber Cancer Institute/Children’s Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol. 1994 Apr;12(4);740-7.
353. Schrappe M, Reiter A, Zimmerraann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Miinster. Leukemia. 2000 Dec;I4(12):2205-22.
354. Schwarzinger I, Valent P, Koller U, et al. Prognostic significance of surface marker expression on blasts of patients with de novo acute myeloblastic leukemia. J Clin Oncol. 1990 Mar;8(3):423-30.
355. SeligerB, Papadileris S, Vogel D, et al. Analysis of the p53 and MDM-2 gene in acute myeloid leukemia. Eur J Haematol. 1996 Sep;57(3);230-40.
356. Sen S, D’Incalci M. Apoptosis. Biochemical events and relevance to cancer chemotherapy. FEBS Lett. 1992 Jul 27;307(1); 122-7.
357. Shearer P, Parham D, Kovnar E, et al. Neurofibromatosis type I and malignancy: review of 32 pediatric cases treated at a single institution. Med Pediatr Oncol. 1994;22(2):78-83.
358. Shen HQ, Tang YM, Yang SL, et al. [Immunophenotyping of 222 children with acute leukemia by multi-color flow cytometry]. Zhonghua Er Ke Za Zhi. 2003 May;41(5);334-7.
359. Shieh SY, Ikeda M, Taya Y, et al, DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 1997 Oct 31;91(3);325-34.
360. Shirlyn B et al.. Text Book of Haematology (2"' ed.), Williams & Wilkins, 1996; 369.361. Shome DK, Ghosh K, Mohanty D, Das KC. Leukaemia in north-west India. Acta
Haematol. I985;73(4):244.
187
362. Shu XO, Ross JA, Pendergrass TW, et al. Parental alcohol consumption, cigarette smoking, and risk of infant leukemia: a Childrens Cancer Group study. J Natl Cancer Inst. 1996 Jan 3;88(1):24-31.
363. Shu XO, Stewart P, Wen WQ, et al. Parental occupational exposure to hydrocarbons and risk of acute lymphocytic leukemia in offspring. Cancer Epidemiol Biomarkers Prev. 1999Sep;8(9);783-91.
364. Shurtleff SA, Buijs A, Behm FG, et al, TEL/AMLi fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia. 1995 Dec;9(12):1985-9.
365. Shuster JJ, Failetta JM, Pullen DJ, et al. Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood. 1990 Jan 1;75(1): 166-73.
366. Sidransky D, Mikkelsen T, Schwechheimer K, et al. Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature. 1992 Feb 27;355(6363):846-7.
367. Sigalas I, Calvert AH, Anderson JJ, et al. Alternatively spliced mdm2 transcripts with loss of p53 binding domain sequences: transforming ability and frequent detection in human cancer. Nat Med. 1996 Aug;2(8):912-7.
368. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia. 2000 Dec;14(12):2247-56
369. Smith BD, Bambach BJ, Vala MS, et al. Inhibited apoptosis and drug resistance in acute myeloid leukaemia. BrJ Haematol. 1998 Sep; 102(4): 1042-9.
370. Smith LJ, Curtis JE, Messner HA, et al. Lineage infidelity in acute leukemia. Blood. 1983 Jun;61(6):l 138-45.
371. Smith M, Bleyer A, Crist W, et al. Uniform criteria for childhood acute lymphoblastic leukemia risk cla.ssification. J Clin Oncol. 1996 Feb;14(2):680-I.
372. Snower DP, Smith BR, Munz UJ, et al. Reevaluation of the periodic acid-Schiff stain in acute leukemia with immunophenotypic analyses. Arch Pathol Lab Med. 1991 Apr;115(4):346-5G.
373. Sobol RE, Mick R, Royston I, et al. Clinical importance of myeloid antigen expression in adult acute lymphoblastic leukemia. N Engl J Med, 1987 Apr 30;316(18):1111-7.
374. Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med. 2000 May;247(5):521-34.
375. Spector LG, Xie Y, Robison LL, et al. Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children’s oncology group. Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):651-5.
376. Sperling C, Buchner T, Creutzig Lf, et al. Clinical, morphologic, cytogenetic and prognostic implications of CD34 expression in childhood and adult de novo AML. Leuk Lymphoma. 1995 May; 17(5-6):417-26.
377. Srinivas G, Kusumakumary P, Nair MK, et al. Mutant p53 protein, Bcl-2/Bax ratios and apoptosis in paediatric acute lymphoblastic leukaemia. J Cancer Res Clin Oncol. 2000Jan;126(l):62-7.
378. Stasi R, Venditti A, Del Poeta G, et al. Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia; analysis of prognostic factors. Cancer. 1996 Jun 15;77(12):2476-88.
379. Steinherz PG, Gaynon PS, Breneman JC, et al. Treatment of patients with acute lymphoblastic leukemia with bulky extrameduHary disease and T-cell phenotype or other poor prognostic features: randomized controlled trial from the Children’s Cancer Group. Cancer. 1998 Feb 1;82(3):600-12.
380. Stennicke HR, Deveraux QL, Humke EW, et al. Caspase-9 can be activated without proteolytic processing. J Biol Chem. 1999 Mar 26;274(I3):8359-62.
188
381. Stirewalt DL, Kopecky KJ, Meshinchi S, et a!. FLT3, RAS, and TP53 mutations in elderly patients with AML. Blood. 2001 Jun 1;97(11);3589-95.
382. Sturm I, Kohne CH, Wolff G, et al. Analysis of the p53/BAX pathway in colorectal cancer: low BAX is a negative prognostic factor in patients with resected liver metastases..f Clin Oncol. 1999 May; 17(5): 1364-74.
383. Styczynski J, Pieters R, Huismans DR, et al. In vitro drug resistance profiles of adult versus childhood acute lymphoblastic leukaemia. Br J Haematol. 2000 Sep; l 10(4);813- 8.
384. Suggs JL, Cruse JM, Lewis RE. Aberrant myeloid marker expression in precursor B- cell and T-cell leukemias. Exp Mol Pathol. 2007 Dec;83(3):47I-3.
385. Susin SA, Lorenzo HK, Zamzami N, et al. Molecular characterization of mitochondrial apoptosis-inducing factor. Nature. 1999 Feb 4;397(67]8):441-6.
386. Suzuki A, Matsuzawa A, Kato M: Involvement of CPP32/Yama-!ike protease in CFT- 1 1-induced death signal transduction pathway. Toxicol In Vitro 1996 Dec 10 (6):693- 700.
387. Swift M. Fanconi’s anaemia in the genetics of neoplasia. Nature. 1971 Apr 9;230(5293):370-3.
388. Tallman MS, Andersen JW, Schiffer CA, et al All-trans-retjnoic acid in acute promyelocytic leukemia. N Engl J Med. 1997 Oct 9; 337(15):1021-8.
389. Taskov H, Dimitrova E, Serbinova M, et al. Immunological subtypes of childhood acute lymphoblastic leukemia in Bulgaria. Leuk Res. 1995 Nov;19(ll):877-81.
390. te Boekhorst FA, de Leeuw K, Schoester M, et al. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood. 1993 Nov 15;82(10):3157-62.
391. Terstappen LW, Safford M, Konemann S, et al. Flow cytometric characterization of acute myeloid leukemia. Part II. Phenotypic heterogeneity at diagnosis. Leukemia. 1992 Jan;6(l):70-80.
392. Tew KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res.1994 Aug 15;54(16):4313-20.
393. Tewari M, Quan LT, O’Rourke K, et al, Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP- ribose) polymera.se. Cell. 1995 Jun 2;81(5);801-9.
394. Thalhammer-Scherrer R, Mitterbauer G, Simonitsch I, et al. The immunophenotype of 325 adult acute leukemias: relationship to morphologic and molecular classification and proposal for a minimal screening program highly predictive for lineage discrimination. Am J Clin Pathol. 2002 Mar,i 17(3):380-9.
395. Thiel E, Kranz BR, Raghavachar A, et al. Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood. 1989 Apr;73(5): 1247-58.
396. Thomas X, Archimbaud E, Charrin C, et al. CD34 expression is associated with major adverse prognostic factors in adult acute lymphoblastic leukemia. Leukemia. 1995 Feb;9(2);249-53.
397. Thomas X, Campos L, Archimbaud E, Shi ZH, Treille-Ritouet D, Anglaret B, Fiere D. Surface marker expression in acute myeloid leukaemia at first relapse. Br J Haematol. 1992May;81(l);40-4.
398. Thomas X, Danaila C, Le QH, et al. Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia. 2001 Dec; 15(12): 1811-22,
399. Tidefelt U, Elmhorn-Rosenborg A, Paul C, et al. Expression of glutathione transferase pi as a predictor for treatment results at different stages of acute nonlymphoblastic leukemia. Cancer Res. 1992 Jun 15;52(12):3281-5.
400. Toledano SR, Lange BJ. Ataxia-telangiectasia and acute lymphoblastic leukemia. Cancer. 1980 Apr I ;45(7): 1675-8
189
401. Traweek ST. Immunophenotypic analysis of acute leukemia. Am J Clin Pathol. 1993 Apr;99(4):504-12.
402. Tritz D, Pettigrew A, Talkington S, et al. Association of CD-15 expression and 1 lq23 translocation in acute leukemias. Mod Pathol 1995; 8: 122.
403. Tyagi BB, Manoharan N, Raina V, Childhood Cancer Incidence in Delhi, 1996-2000 Indian journal of medical & paediatric oncology vol. 2006; 27(4): 13-18.
404. Uckun FM, Sather HN, Gaynon PS, et al. Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia; a report from the Children’s Cancer Group. Blood. 1997 Jul l;90(l):28-35.
405. van den Heuvel-Eibrink MM, Sonneveld P, Pieters R. The prognostic significance of membrane transport-associated nuiltidrug resistance (MDR) proteins in leukemia. Int J Clin Pharmacol Ther. 2000 Mar;38(3):94-110.
406. van der Kolk DM, de Vries EG, Noordhoek L, et a l Activity and expression of the multidrug resistance proteins P-glycoprotein, MRPl, MRP2, MRP3 and MRP5 in de novo and relapsed acute myeloid leukemia. Leukemia. 2001 Oct;15(10):1544-53.
407. van Duijn CM, van Steensel-Moll HA, Coebergh JW, el al. Risk factors for childhood acute non-lymphocytic leukemia: an association with maternal alcohol consumption during pregnancy? Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):457-60.
408. van Stijn A, van der Pol MA, Kok A, et al. Differences between the CD34+ and CD34- blast compartments in apoptosis resistance in acute myeloid leukemia. Haematologica. 2003 May;88(5):497-508.
409. van Zutven LJ, van Drunen E, de Bont JM, et al. CDKN2 deletions have no prognostic value in childhood precursor-B acute lymphoblastiic leukaemia. Leukemia. 2005 Jul; 19(7): 1281-4.
410. Vanhaeke DR, Bene MC, Garand R, et al. Expression and long-term prognostic value of CD34 in childhood and adult acute lymphoblastic leukemia. Leak Lymphoma. 1995 Dec;20( 1-2): 137-42.
411. Vaughan WP, Civin Cl, Weisenburger DD, et al. Acute leukemia expressing the normal human hematopoietic stem cell membrane glycoprotein CD34 (MY 10). Leukemia. 1988 Oct;2(lO):66l-6.
412. Venditti A, Del Poeta G, Buccisano F, et al. Minimally differentiated acute myeloid leukemia (AML-MO): comparison of 25 cases with other French-American-British subtypes. Blood. 1997 Jan 15;89(2):621-9.
413. Venditti A, Del Poeta G, Buccisano F, et al. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. Leukemia. 1998 Jul; 12(7): 1056-63.
414. Venditti A, Del Poeta G, Maurillo L, et al. Combined analysis of bcl-2 and MDRl proteins in 256 cases of acute myeloid leukemia. Haematologica. 2004 Aug;89(8):934- 9.
415. Verhagen AM, Ekert PG, Pakusch M, et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing lAP proteins. Cell. 2000 Jul 7;102(l):43-53.
416. Vermes I, Haanen C, Steffens-Nakken H, et al. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995 Jul 17;184(1):39-51.
417. Vidriales MB, Orfao A, Gonzalez M, et al. Expression of NK and lymphoid-associated antigens in blast cells of acute myeloblastic leukemia. Leukemia. 1993 Dec;7(12):2026-9.
418. Virchow R, Weisses Blut. In: Neue Notizen aus dem Gebiete der Natur- und Heilkunde, (eds. by L. F. v. Froriep & R. Froriep). Berlin. 1845 (36): 151-56.
419. Vitale A, Guarini A, Ariola C, et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in
190
patients enrolled in the GIMEMA LAL 0496 protocol. Blood. 2006 Jan 15;107(2):473-9.
420. Vitale A, Guarini A, Ariola C, et al. Ab.sence of prognostic impact of CD 13 and/or CD33 antigen expression in adult acute lymphoblastic leukemia. Results of the GIMEMA ALL 0496 trial. Haematologica. 2007 Mar;92(3):342-8.
42L Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000 Nov 16;408(6810);307-10.
422. Volm M, Koomagi R, Stammler G, et al. Prognostic implications of cyclins (Dl, E, A), cyclin-dependent kinases (CDK2, CDK4) and tumor-suppressor genes (pRB, pI6INK4A) in childhood acute lymphoblastic leukemia. Int J Cancer. 1997 Oct 21;74(5):508-12.
423. Warrell RP Jr, Maslak P, Eardley A, et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid; an update of the New York experience. Leukemia. 1994 Jun;8(6);929-33.
424. Weick JK, Kopecky KJ, Appelbaum FR, et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1996 Octl5;88(8):2841-51.
425. Weinstein HJ. Acute Myeloid Leukemia. In; Childhood Leukemias. Pui CH (eds). UK: Cambridge University Press; 1999. 322-35.
426. Westerbeek RM, Blair V, Eden OB, et al. Seasonal variations in the onset of childhood leukaemia and lymphoma. Br J Cancer. 1998 Jui;78(l):119-24.
427. Wickremasinghe RG, Hoffbrand AV. Biochemical and genetic control of apoptosis: relevance to normal hematopoiesis and hematological malignancies. Blood. 1999 Jun l;93(Il):3587-600.
428. Wiersma SR, Ortega J, Sobel E, et al. Clinical importance of myeloid-antigen expression in acute lymphoblastic leukemia of childhood. N Engl J Med, 1991 Mar 21:324(12):800-8.
429. Willis AE, Lindahl T. DNA ligase I deficiency in Bloom’s syndrome. Nature. 1987 Jan 22-28;325(6102);355-7.
430. Woods WG, Roloff JS, Lukens JN, et al. The occurrence of leukemia in patients with the Shwachman syndrome. J Pediatr. 1981 Sep;99(3):425-8.
431. Wuchter C, Karawajew L, Ruppert V, et al. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics. Leukemia. 1999 Dec; 13(12); 1943-53.
432. Wuchter C, Karawajew L, Ruppert V, et al. Constitutive expression levels of CD95 and Bcl-2 as well as CD95 function and spontaneous apoptosis in vitro do not predict the response to induction chemotherapy and relapse rate in childhood acute lymphoblastic leukaemia. Br J Haematol, 2000 Jul;l 10(1): 154-60.
433. Wuchter C, Krappmann D, Cai Z, et al. In vitro susceptibility to TRAIL-induced apoptosis of acute leukemia cells in the context of TRAIL receptor gene expression and constitutive NF-kB activity. Leukemia. 2001 Jun;I5(6);921-8.
434. Wyllie AH, Kerr JF, Currie AR. Ceil death; the significance of apoptosis. Int Rev Cytol. 1980;68:251-306.
435. Xiao ZX, Chen J, Levine AJ, et al. Interaction between the retinoblastoma protein and the oncoprotein MDM2. Nature. 1995 Jun 22;375(6533):694-8.
436. Yamada S, Kongo T, Okada S, et al. Clinical relevance of in vitro chemoresistance in childhood acute myeloid leukemia. Leukemia. 2001 Dec; 15(12): 1892-7.
437. Yenerel MN, Atamer T, Yavuz AS, et al. Myeloid antigen expression provides favorable outcome in patients with adult acute lymphoblastic leukemia: a single-center study. Ann Hematol, 2002 Sep;81(9):498-503.
191
438. Yeole BB, Jussawalla DJ, Advani SH. Descriptive epidemiology of leukaemias in Greater Mumbai. Natl Med J India. 1998 May-Jun;! 1{3): 116-9.
439. Yonish-Rouach E, Resnitzky D, Lotem J, et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature, 1991 Jul 25;352(6333):345-7.
440. Young JL Jr, Miller RW. Incidence of malignant tumors in U. S. children. J Pediatr. 1975 Feb;86(2):254-8.
441. Zahm SH, Ward MH. Pesticides and childhood cancer. Environ Health Perspect. 1998 Jun;106 Suppl 3:893-908.
442. Zheng J, Wang X, Hu Y, et al. A correlation study of immunophenotypic, cytogenetic, and clinical features of 180 AML patients in China. Cytometry B Clin Cytom. 2008 3an;74(l);25-9.
443. Zhou M, Yeager AM, Smith SD, et al. Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene. Blood. 1995 Mar 15;85(6):1608-14.
444. Zhu H, Niu T, Meng W, et al. [Immunophenotype of acute leukemia and its clinical significance]. Hua Xi Yi Ke DaXue Xue Bao. 2002 Jan;33(l):l 18-20.
445. Zochbauer S, Schwarzinger I, Strobl H, et al. Relationship between MDRl gene and surface markers in acute myeloid leukemia. Anticancer Res. 1997 Jan-Feb; 17(1 B):749-52.
446. Zou H, Henzel WJ, Liu X, et al. Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 1997 Aug 8;90(3):405-13.
447. Zubercova O, Babusfkova 0. The multidrug resistance in human leukemias. Minireview. Neoplasma. 1998;45(2):53-9.
448. Zutter MM, Martin PJ, Hanke D, et al. CD7+ acute non-lymphocytic leukemia: evidence for an early multipotential progenitor. Leuk Res. 1990; 14(1 ):23-6.
449. Zwaan CM, Kaspers GJ, Pieters R, et al. Cellular drug resistance profiles in childhood acute myeloid leukemia; differences between FAB types and comparison with acute lymphoblastic leukemia. Blood. 2000 Oct 15;96(8):2879-86.
192
